Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giuseppe Lanzarone
Institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
University of Turin
Observed institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
University of Turin
ORCID:
0000-0002-8114-0798
Observed ORCID:
0000-0002-8114-0798
OpenAlex ID:
A5057954140
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
2020
·
Bianca Rocca
, Alberto Tosetto
, et al.
·
Blood
·
114
PDF
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
2018
·
Valerio De Stefano
, Bianca Rocca
, et al.
·
Blood Cancer Journal
·
43
PDF
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
2022
·
Federica Martella
, Marco Cerrano
, et al.
·
Annals of Hematology
·
40
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
2018
·
Elena Crisà
, Daniela Cilloni
, et al.
·
British Journal of Haematology
·
35
PDF
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
2024
·
Bianca Rocca
, Alberto Tosetto
, et al.
·
American Journal of Hematology
·
28
PDF
Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges
2023
·
Matteo Olivi
, Federica Di Biase
, et al.
·
Current Treatment Options in Oncology
·
26
Can pegylated interferon improve the outcome of polycythemia vera patients?
2017
·
Elena Crisà
, Marco Cerrano
, et al.
·
Journal of Hematology & Oncology
·
24
PDF
Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
2021
·
Alberto Tosetto
, Bianca Rocca
, et al.
·
Clinical Pharmacology & Therapeutics
·
10
PDF
Validation of SIE / SIES / GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax
2023
·
Vincenzo Apolito
, Giulia Arrigo
, et al.
·
British Journal of Haematology
·
9
PDF
Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm
2025
·
Elena Crisà
, Irene Dogliotti
, et al.
·
Cancers
·
8
PDF
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study
2025
·
Gianluca Cavallaro
, Davide Lazzarotto
, et al.
·
Bone Marrow Transplantation
·
8
PDF
The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
2021
·
Giuseppe Lanzarone
, Matteo Olivi
·
Medicina
·
6
PDF
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
2025
·
Giovanni Marconi
, Elisabetta Petracci
, et al.
·
American Journal of Hematology
·
5
PDF
Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study
2023
·
Matteo Dragani
, Roberta Agrippino
, et al.
·
Blood
·
5
Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus
2025
·
Valentina Giai
, Tiziana Rosso
, et al.
·
Cancer
·
4
Repurposing the Whole Expression Transcriptome Assay for the Genetic Diagnosis of T-Cell Acute Lymphoblastic Leukemia and Lymphoma
2025
·
Valentina Bardelli
, Silvia Arniani
, et al.
·
Journal of Molecular Diagnostics
·
4
PDF
Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia
2022
·
Elena Inzoli
, Elena Crisà
, et al.
·
European Journal Of Haematology
·
4
PDF
The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs
2023
·
Valentina Giai
, Fabio Stagno
, et al.
·
Blood
·
3
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms
2021
·
Achille Pich
, Eloise Beggiato
, et al.
·
Expert Review of Hematology
·
3
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
2023
·
Irene Urbino
, Carolina Secreto
, et al.
·
Leukemia Research
·
2
The c.2031–2A>C MPO gene variant and the predisposition to myeloid neoplasms
2025
·
Maria Crocioni
, Carlotta Nardelli
, et al.
·
Annals of Hematology
·
1
PDF
CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
2024
·
Valentina Giai
, Tiziana Rosso
, et al.
·
Blood
·
1
PDF
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in Progress
2026
·
Jasson Villarreal Hernandez
, Javier Octavio Díaz Carbonero
, et al.
·
OncoTargets and Therapy
PDF
Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study
2026
·
Gianluca Cavallaro
, Davide Lazzarotto
, et al.
·
Bone Marrow Transplantation
PDF
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation
2026
·
Giulia Benevolo
, Giuseppe Lanzarone
, et al.
·
Expert Review of Hematology
Show more works
View as search
Works count:
34
Citation count:
383
H-index:
9
I10-index:
8
Year
Topic
Type